http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Zhuoqi Li,Shuhuan Liu,Xiaotang Ren,Mathew Adefusika Adekoya,Jun Zhang,Shuangying Liu 한국원자력학회 2022 Nuclear Engineering and Technology Vol.54 No.2
The 3 MeV proton irradiation effects on SiGe low noise amplifier (LNA) (NXP BGU7005) performanceunder different voltage supply VCC (0 V, 2.5 V) conditions were firstly experimental studied in thispresent work. The S parameters including S11, S22, S21, 1 dB compression point and noise figure (NF) of thetest samples under different bias voltage supply were measured and compared before and after 3 MeVproton irradiation. The total proton irradiation fluence was 1 1015 protons/cm2. The maximumdegradation quantities of the gain S21 and NF of the test samples under zero bias are measuredrespectively 1.6 dB and 1.2 dB. Compared with the samples under 2.5 V bias supply, the maximumdegradation of S21 and NF are respectively 1.1 dB and 0.8 dB in the whole frequency band. It is noteworthy that the gain and NF of SiGe LNAs under zero-bias mode suffer enhanced degradation comparedwith those under normal bias supply. The key influence factors are discussed based on the correlation ofthe SiGe device and the LNA circuit. Different process of the ionization damage and displacement damageunder zero-bias and 2.5 V bias voltage supply contributed to the degradation difference. The underlyingphysical mechanisms are analyzed and investigated
Liangliang Wang,Shuangying Li,Da Zhu,Yu Qin,Xiaoli Wang,Zhenya Hong,Zhiqiang Han 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.4
Objective: To evaluate the effectiveness and safety of nab-paclitaxel plus platinum as first-line chemotherapy for ovarian cancer (OC). Methods: Patients administered platinum combined with nab-paclitaxel as first-line chemotherapy for epithelial OC, fallopian tube cancer, or primary peritoneal cancer from July 2018 to December 2021 were retrospectively evaluated. The primary outcome was progression-free survival (PFS). Adverse events (AEs) were examined. Subgroup analysis was performed. Results: Seventy-two patients (median age, 54.5 years; range, 20.0–79.0 years) were evaluated, including 12 and 60 administered neoadjuvant therapy and primary surgery with subsequent chemotherapy, respectively. The median follow-up duration was 25.6 months, and the median PFS was 26.7 (95% confidence interval [CI]=24.0–29.3) months in the whole patient population. In the neoadjuvant subgroup, the median PFS was 26.7 (95% CI=22.9–30.5) months vs. 30.1 (95% CI=23.1–37.1) months in the primary surgery subgroup. Twenty-seven patients were administered nab-paclitaxel plus carboplatin and had a median PFS of 30.3 (95% CI=not available [NA]–NA) months. The commonest grade 3–4 AEs included anemia (15.3%), white blood cell decreased (11.1%), and neutrophil count decreased (20.8%). No drug-related hypersensitivity reactions occurred. Conclusion: Nab-paclitaxel plus platinum as first-line treatment in OC was associated with a favorable prognosis and was tolerable in patients with OC.